Zila to Introduce New and Improved Ester-C; Commercialization Efforts Nearly Complete for New Patented Product
May 02 2006 - 8:30AM
Business Wire
Zila, Inc., (Nasdaq: ZILA) announced that its wholly owned
subsidiary, Zila Nutraceuticals, Inc., manufacturer of Ester-C(R)
and Ester-E(R), has developed a new and improved form of its
Ester-C product and that the patent protection for this new form of
Ester-C extends until 2019. Ester-C is the most widely recognized
branded nutraceutical ingredient in the United States. The new
product offers all the benefits of Zila's traditional Ester-C plus
an additional metabolite with new benefits. Following years of
research and development, the new Ester-C product is nearly ready
for commercial distribution. "We are extremely pleased to be able
to continue to provide a patent protected and superior form of
vitamin C to the loyal consumers of our Ester-C product. This new
product has been designed to enhance the antioxidant and
anti-carcinogenic potential of our existing Ester-C formula and the
patent protection for it will last until 2019. We will be working
with our customers to assure a smooth transition to this new
product as we get closer to the product launch date." said Douglas
D. Burkett, Ph.D., Chairman, Chief Executive Officer and President
of Zila, Inc. About Ester-C(R) Ester-C is an advanced form of
vitamin C that is pH neutral, providing a form that is gentler on
the stomach than regular vitamin C. During the patented process of
producing Ester-C, the vitamin C undergoes changes similar to those
that occur in the body, which results in enhanced levels of
valuable metabolites. Ester-C has also been clinically proven to
work in the immune system for 24 hours. Additional clinical studies
and product claims are planned. About Ester-E(R) Ester-E is an
advanced form of vitamin E containing d-alpha tocopheryl phosphates
(or "TP" for short). Until recently, scientists were unaware of
this important source of vitamin E in the body. Research suggests
that the human body may convert other forms of vitamin E into TP in
order to protect the vitamin's antioxidant strength. Scientists are
now able to replicate this natural form of vitamin E (Ester-E) in a
patented process, preserving vitamin E's natural health benefits so
that it can be more effectively used by the body. These statements
have not been evaluated by the Food and Drug Administration. This
product is not intended to diagnose, treat, cure or prevent any
disease. Visit www.Ester-E.com or www.Ester-C.com for more
information about the "Ester" line of premium products. About Zila,
Inc. Zila, Inc., headquartered in Phoenix, is an innovator in
preventative healthcare technologies and products, focusing on
enhanced body defense and the detection of pre-disease states. Zila
has three business units: -- Zila Biotechnology, a research,
development and licensing business specializing in
pre-cancer/cancer detection through its patented Zila(R) Tolonium
Chloride and OraTest(R) technologies. -- Zila Pharmaceuticals,
marketer of products to promote oral health and prevent oral
disease, including ViziLite(R) Plus oral examination kits and
Peridex(R) prescription periodontal rinse. -- Zila Nutraceuticals,
manufacturer and marketer of Ester-C(R) and Ester-E(R), branded,
highly effective forms of Advanced Protection vitamins C and E. --
For more information about Zila, visit www.zila.com. This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. These forward-looking statements
are based largely on Zila's expectations or forecasts of future
events, can be affected by inaccurate assumptions and are subject
to various business risks and known and unknown uncertainties, a
number of which are beyond the Company's control. Therefore, actual
results could differ materially from the forward-looking statements
contained herein. A wide variety of factors could cause or
contribute to such differences and could adversely impact revenues,
profitability, cash flows and capital needs. There can be no
assurance that the forward-looking statements contained in this
press release will, in fact, transpire or prove to be accurate. For
a more detailed description of these and other cautionary factors
that may affect Zila's future results, please refer to Zila's Form
10-K for its fiscal year ended July 31, 2005.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jul 2023 to Jul 2024